IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

Artificial Intelligence in Pharmaceutical Sciences: A Review

Sunil D Kachkure[1], Shankar S Khandare[1], Prerna M Thorat[1], Yogesh D Dhadge[1], Priyanka D Bajare[1]
Raosaheb Patil Danve College of Pharmacy, Badarpur, Maharashtra

Abstract: *Artificial Intelligence (AI) is rapidly transforming the pharmaceutical field by enhancing efficiency, accuracy, and innovation across the entire drug development and healthcare delivery process. The pharmaceutical industry traditionally faces challenges such as high research and development costs, prolonged timelines, low success rates, and increasing regulatory complexity. AI technologies, including machine learning, deep learning, natural language processing, and computer vision, offer powerful tools to overcome these limitations by enabling data-driven decision-making and predictive analytics. This review provides a comprehensive overview of the applications of AI in pharmaceutical sciences, covering drug discovery and design, preclinical evaluation, clinical trial optimization, pharmaceutical manufacturing, pharmacovigilance, and pharmacy practice. In drug discovery, AI accelerates target identification, lead optimization, and virtual screening, significantly reducing time and cost. During clinical development, AI improves patient recruitment, trial monitoring, and outcome prediction through analysis of real-world and clinical data. AI-based systems also play a critical role in manufacturing by ensuring quality control, process optimization, and supply chain management. Furthermore, AI enhances pharmacovigilance by automating adverse drug reaction detection and signal analysis, thereby improving drug safety and regulatory compliance. In clinical and community pharmacy practice, AI supports medication therapy management, personalized dosing, drug interaction screening, and patient adherence. Despite these advantages, challenges such as data quality, ethical concerns, model transparency, and regulatory acceptance remain significant. Overall, AI represents a transformative and indispensable technology in modern pharmaceutical sciences, with strong potential to advance personalized medicine and patient-centered healthcare*

Keywords: Artificial Intelligence; Machine Learning; Drug Discovery; Clinical Trials; Pharmacovigilance; Pharmacy Practice

I. INTRODUCTION

The pharmaceutical industry is undergoing a major digital transformation due to increasing research complexity, rising development costs, and growing demand for safer and more effective medicines. Conventional drug discovery and development is a resource-intensive process, often requiring 10–15 years and an estimated USD 2–3 billion to bring a single drug to market, with failure rates exceeding 90%, particularly during clinical trials [1,2]. These challenges necessitate innovative computational approaches capable of improving efficiency and decision-making throughout the drug life cycle. Artificial Intelligence (AI) refers to computational systems that simulate human intelligence by performing tasks such as learning, pattern recognition, prediction, and reasoning. AI includes multiple subfields such as machine learning (ML), deep learning (DL), natural language processing (NLP), and computer vision, all of which have demonstrated strong relevance to pharmaceutical sciences [3]. Recent advances in high-performance computing, cloud platforms, and availability of large biomedical datasets have significantly accelerated AI adoption in healthcare and drug research.AI is increasingly applied across the pharmaceutical value chain, from target identification and lead optimization to clinical trial design, manufacturing, pharmacovigilance, and pharmacy practice [4]. In drug discovery, AI-based algorithms analyze genomic, proteomic, and chemical data to identify novel drug targets and optimize lead compounds, reducing early-stage attrition [5]. AI-driven virtual screening and de novo drug design have enabled the identification of promising candidates in a fraction of the time required by traditional methods [6]. During clinical development, AI

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

enhances patient recruitment, trial monitoring, and outcome prediction by integrating electronic health records (EHRs), real-world evidence, and wearable data [7]. In manufacturing, AI supports quality-by-design (QbD), process optimization, and predictive maintenance, ensuring regulatory compliance and product consistency [8]. Furthermore, AI-based pharmacovigilance systems enable rapid detection of adverse drug reactions (ADRs) through automated signal detection and text mining of safety databases [9].The global market for AI in pharmaceuticals is expanding rapidly and is projected to grow at a compound annual growth rate (CAGR) of over 25%, reflecting increasing industry investment and regulatory interest [10]. However, challenges such as data quality, algorithm transparency, ethical concerns, and regulatory validation remain barriers to widespread adoption. Despite these limitations, AI is expected to play a pivotal role in advancing precision medicine, personalized therapy, and patient-centered pharmaceutical care. This review aims to comprehensively discuss the applications, advantages, challenges, and future prospects of artificial intelligence in the pharmaceutical field..

II. OVERVIEW OF ARTIFICIAL INTELLIGENCE

Artificial Intelligence (AI) is defined as the ability of computer systems to perform tasks that typically require human intelligence, such as learning, reasoning, problem-solving, perception, and decision-making. In healthcare and pharmaceutical sciences, AI enables the analysis of large, complex, and heterogeneous datasets that are difficult to interpret using traditional statistical methods [11]. The rapid evolution of AI has been driven by advances in computational power, availability of big data, cloud computing, and sophisticated algorithms.

AI systems can broadly be categorized into rule-based systems and learning-based systems. Early rule-based expert systems relied on predefined rules and human expertise but lacked adaptability. In contrast, modern AI systems are largely data-driven and capable of learning from experience, making them more suitable for dynamic and complex pharmaceutical applications [12].A major subset of AI is Machine Learning (ML), which allows algorithms to learn patterns from data and make predictions without explicit programming. ML approaches include supervised learning, unsupervised learning, and reinforcement learning, each widely used in pharmaceutical research for tasks such as drug target prediction, compound classification, and optimization of therapeutic regimens [13]. Deep Learning (DL), a more advanced form of ML, uses multi-layered artificial neural networks and has demonstrated superior performance in image recognition, molecular modelling, and genomic data analysis [14].Another important AI domain is Natural Language Processing (NLP), which enables machines to understand and analyze unstructured textual data such as scientific literature, clinical trial reports, regulatory documents, and adverse event narratives [15]. Computer vision, which focuses on the interpretation of visual data, is increasingly used in histopathological image analysis, quality inspection in manufacturing, and automated microscopy [16].Overall, AI provides a foundational framework for automation, prediction, and intelligent decision-making in pharmaceutical sciences. Its integration supports faster innovation, improved accuracy, and data-driven strategies across the pharmaceutical value chain, forming the basis for advanced applications discussed in subsequent sections.

III. APPLICATIONS OF AI IN THE PHARMACEUTICAL FIELD

3.1 Drug Discovery and Design

Drug discovery and design is one of the most impactful areas where Artificial Intelligence (AI) has demonstrated significant potential. Traditional drug discovery is a lengthy, expensive, and high-risk process involving target identification, hit discovery, lead optimization, and preclinical validation. AI-driven approaches enable faster and more accurate decision-making by analyzing large-scale biological, chemical, and pharmacological datasets [17].

3.2. Target Identification and Validation

AI algorithms analyze genomic, proteomic, transcriptomic, and metabolomic data to identify novel disease-associated targets. Machine learning (ML) models can detect complex biological patterns and predict target–disease associations with higher accuracy than conventional methods [18]. AI-based network pharmacology and systems biology approaches further assist in understanding disease pathways and validating drug targets.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

3.3. Virtual Screening and Hit Identification

AI significantly improves **virtual screening** by rapidly evaluating millions of chemical compounds to identify potential hits. Deep learning models, quantitative structure–activity relationship (QSAR) techniques, and molecular docking simulations help predict binding affinity, selectivity, and biological activity of compounds, thereby reducing experimental workload and cost [19]. Compared to traditional high-throughput screening, AI-based virtual screening achieves higher hit rates with reduced resource utilization.

3.4. Lead Optimization and De Novo Drug Design

AI plays a crucial role in lead optimization by predicting pharmacokinetic properties, toxicity, solubility, and bioavailability of candidate molecules. Generative AI models, including variational autoencoders and generative adversarial networks, are capable of designing novel chemical entities with optimized therapeutic profiles [20]. These approaches allow rapid modification of molecular structures to improve efficacy and reduce adverse effects.

3.5. Prediction of Drug-Likeness and Safety

AI tools can predict absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties at early stages of drug development. Early identification of toxic or poorly bioavailable compounds reduces late-stage failures and enhances overall R&D efficiency [21]. Several AI-designed molecules have successfully progressed into clinical trials, highlighting the real-world applicability of these technologies [22].Overall, AI has revolutionized drug discovery and design by shortening development timelines, lowering costs, and increasing success rates. Its integration is shifting pharmaceutical research toward a more predictive, data-driven, and efficient paradigm.

Fig 1: AI Application Framework in the Pharmaceutical Industry

3.6 Preclinical Research

Preclinical research aims to evaluate the safety, efficacy, and biological behavior of drug candidates before human testing. Artificial Intelligence (AI) has significantly improved this stage by enabling accurate prediction of pharmacokinetics (PK), pharmacodynamics (PD), toxicity, and drug–drug interactions (DDIs) using in silico models [23]. Machine learning algorithms analyze chemical structures and biological datasets to predict absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, thereby identifying unsuitable candidates at an early stage.AI-based toxicological models reduce dependence on animal experiments by simulating biological responses and predicting organ-specific toxicity, mutagenicity, and carcinogenicity [24]. These approaches not only reduce cost and time but also support ethical principles by minimizing animal usage. Overall, AI-driven preclinical evaluation enhances decision-making and increases the probability of clinical success

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

3.7 Clinical Trials

Clinical trials are among the most expensive and failure-prone stages of drug development. AI improves clinical trial efficiency by optimizing patient recruitment, trial design, and monitoring. By analyzing electronic health records (EHRs), genomic data, and real-world evidence, AI algorithms can identify eligible patients, predict enrollment rates, and reduce recruitment delays [25].Predictive analytics helps in selecting optimal trial sites, forecasting patient dropout risks, and detecting protocol deviations in real time [26]. AI-powered monitoring tools also enable adaptive trial designs and early identification of safety concerns, thereby improving trial outcomes and reducing overall development timelines.

3.8 Pharmaceutical Manufacturing

In pharmaceutical manufacturing, AI supports process optimization, quality assurance, and predictive maintenance. AI-driven process analytical technology (PAT) and quality-by-design (QbD) frameworks enable real-time monitoring of critical process parameters, ensuring product consistency and regulatory compliance [27].Machine learning models predict equipment failures, optimize batch production, and improve supply chain management by forecasting demand and minimizing wastage [28]. Smart manufacturing systems enhance operational efficiency, reduce human error, and support compliance with Good Manufacturing Practices (GMP).

3.9 Pharmacovigilance and Drug Safety

Pharmacovigilance involves the detection, assessment, and prevention of adverse drug reactions (ADRs). AI-driven systems automate ADR detection and signal identification by analyzing large datasets from spontaneous reporting systems, clinical databases, and social media using natural language processing (NLP) and data mining techniques [29].These systems improve the speed and accuracy of safety signal detection and support timely regulatory decision-making. AI-based pharmacovigilance enhances post-marketing surveillance and strengthens patient safety by enabling proactive risk management [30].

3.10 Pharmacy Practice and Healthcare Delivery

AI has an increasing role in clinical and community pharmacy practice by supporting medication therapy management, drug interaction screening, dose optimization, and personalized treatment planning. AI-powered decision support systems assist pharmacists in minimizing medication errors and improving therapeutic outcomes [31].Chatbots, mobile health applications, and virtual assistants improve patient education, medication adherence, and access to pharmaceutical care, particularly in telepharmacy and remote healthcare settings [32]. These technologies enhance patient-centered care and support the evolving role of pharmacists in digital healthcare systems.

Table 1: Applications of Artificial Intelligence Across the Drug Life Cycle

Drug life cycle stage	Ai techniques used	Key applications	Benefits
Target identification & validation	Machine learning, network analysis	Identification of disease-associated targets, pathway analysis, biomarker discovery	Faster target selection, reduced early-stage failure
Drug discovery & design	Deep learning, qsar, generative ai	Virtual screening, lead identification, de novo drug design, structure optimization	Reduced time and cost, improved hit-to-lead ratio
Preclinical research	Ml, in silico modeling	Admet prediction, toxicity assessment, drug–drug interaction prediction	Early failure detection, reduced animal usage
Clinical trials	Ml, nlp, predictive analytics	Patient recruitment, trial design, site selection, real-time monitoring	Improved trial efficiency, reduced dropout rates
Pharmaceutical manufacturing	Ml, computer vision	Process optimization, quality control, predictive maintenance	Enhanced product consistency, gmp compliance

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

Supply chain management	Ml, forecasting models	Demand forecasting, inventory management, logistics optimization	Reduced wastage, improved availability
Pharmacovigilance	NLP, Data Mining	ADR detection, signal identification, risk assessment	Faster safety signal detection, improved patient safety
Regulatory affairs	Nlp, document automation	Regulatory submissions, compliance monitoring, document review	Reduced regulatory burden, faster approvals
Pharmacy practice	Clinical decision support systems, ai chatbots	Medication therapy management, dose optimization, patient counseling	Reduced medication errors, personalized care
Post-marketing surveillance	Ml, real-world data analytics	Effectiveness monitoring, long-term safety evaluation	Continuous benefit–risk assessment

IV. REGULATORY AND ETHICAL CONSIDERATIONS

The rapid integration of Artificial Intelligence (AI) into pharmaceutical research, healthcare delivery, and drug regulation has raised important regulatory and ethical challenges. Regulatory agencies worldwide are actively developing frameworks to ensure that AI-based tools used in drug discovery, clinical trials, pharmacovigilance, and patient care are **safe, reliable, and transparent** [33]. Unlike traditional software, AI systems—particularly those based on machine learning—can evolve over time, necessitating continuous oversight and validation.

Validation and explainability are critical regulatory requirements. AI models must demonstrate consistent performance, robustness, and reproducibility across diverse datasets. Explainable AI (XAI) is increasingly emphasized to ensure that decisions made by algorithms can be interpreted and justified by healthcare professionals and regulators, thereby supporting trust and accountability [34].



Fig 2. Regulatory and Ethical Considerations Artificial Intelligence (AI)

Data privacy and security represent major ethical concerns, as AI systems rely heavily on large volumes of sensitive patient data such as electronic health records and genomic information. Compliance with data protection regulations, including the General Data Protection Regulation (GDPR) and national health data laws, is essential to safeguard patient confidentiality and prevent misuse of data [35]. **Bias and fairness** are additional ethical challenges. AI algorithms trained on non-representative datasets may produce biased outcomes, potentially leading to health disparities. Regulators and developers must ensure diversity in training datasets and regularly audit AI systems for bias and performance inconsistencies [36]. Regulatory authorities such as the **U.S. Food and Drug Administration (FDA), European**

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

Medicines Agency (EMA), and **World Health Organization (WHO)** have issued guidance documents to promote the responsible use of AI in healthcare and pharmaceuticals [37]. Establishing clear accountability frameworks—defining responsibility among developers, manufacturers, and healthcare professionals—is essential for safe implementation.

V. CHALLENGES AND LIMITATIONS

Despite the significant potential of Artificial Intelligence (AI) in pharmaceutical sciences, several challenges and limitations hinder its widespread and effective implementation. One of the primary challenges is data quality and availability. AI systems rely on large, high-quality, and well-annotated datasets; however, pharmaceutical and clinical data are often fragmented, incomplete, heterogeneous, and subject to reporting bias, which can adversely affect model performance and reliability [38].Another major limitation is the lack of transparency and explainability in complex AI models, particularly deep learning algorithms. These "black-box" systems make it difficult for researchers, clinicians, and regulators to understand how decisions are generated, limiting trust and regulatory acceptance [39]. This issue is especially critical in high-risk applications such as clinical decision support and drug safety evaluation. Bias and generalizability pose additional concerns. AI models trained on non-diverse or unrepresentative datasets may produce biased predictions, potentially leading to inequitable healthcare outcomes and reduced effectiveness across different populations [40]. Continuous model validation and dataset diversification are required to address these concerns. The high cost of implementation and infrastructure requirements also limit AI adoption, particularly in small pharmaceutical companies and developing countries. Investment in advanced computing resources, skilled personnel, and data management systems is essential but often financially challenging [41]. Furthermore, regulatory uncertainty and lack of standardized guidelines for AI validation, approval, and lifecycle management create barriers to implementation. Ethical concerns related to data privacy, cybersecurity risks, and accountability further complicate AI integration into pharmaceutical workflows [42].

VI. FUTURE PERSPECTIVES

The future of Artificial Intelligence (AI) in the pharmaceutical field is expected to move toward **fully integrated,** end-to-end digital drug development pipelines, where AI supports every stage from target identification to post-marketing surveillance. The convergence of AI with big data analytics, cloud computing, and high-throughput experimental technologies will enable faster, more cost-effective, and data-driven pharmaceutical innovation [43].

One of the most promising future directions is personalized and precision medicine. AI-driven analysis of genomic, proteomic, metabolomic, and real-world patient data will allow the development of tailored therapies based on individual patient characteristics, disease subtypes, and treatment responses.

VII. DISCUSSION

The present review highlights the expanding role of Artificial Intelligence (AI) across the pharmaceutical drug life cycle, emphasizing its potential to address long-standing challenges related to efficiency, cost, and decision-making. AI-driven approaches have demonstrated clear advantages over traditional methods, particularly in drug discovery and preclinical research, where predictive modelling and in silico simulations significantly reduce time, resource consumption, and attrition rates [17,23]. The ability of AI to analyze multidimensional biological and chemical data has shifted pharmaceutical research from a trial-and-error approach toward a more predictive and data-driven paradigm. In clinical development, AI-enabled patient recruitment, trial optimization, and real-time monitoring have shown promise in improving trial success rates and reducing delays, which are major contributors to drug development failure [25,26]. Similarly, AI-supported manufacturing and supply chain management align with Industry 4.0 principles, ensuring product quality, regulatory compliance, and operational efficiency [27,28]. The integration of AI into pharmacovigilance has further strengthened post-marketing surveillance by enabling rapid detection of adverse drug reactions through automated signal detection and natural language processing [29,30].Despite these advancements, the discussion also underscores critical limitations that must be addressed. Challenges related to data quality, algorithm transparency, bias, and regulatory uncertainty remain significant barriers to large-scale implementation [38–40]. The "black-box" nature of complex AI models limits interpretability, which is essential for regulatory approval and clinical trust. Furthermore, disparities in data

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

representation may affect the generalizability of AI models across diverse patient populations. Ethical and regulatory considerations are central to the responsible adoption of AI in pharmaceuticals. Regulatory agencies are increasingly recognizing the need for adaptive frameworks that balance innovation with patient safety, data privacy, and accountability [33,37]. Collaboration among academia, industry, technology developers, and regulators is therefore critical to ensure standardization, validation, and ethical governance. Overall, AI should be viewed not as a replacement for human expertise but as a decision-support tool that augments scientific judgment. Continued interdisciplinary collaboration, transparent model development, and regulatory alignment will be essential to fully realize the transformative potential of AI in pharmaceutical sciences.

VIII. CONCLUSION

Artificial Intelligence (AI) has emerged as a transformative force in the pharmaceutical field, offering innovative solutions to long-standing challenges associated with drug discovery, development, manufacturing, and healthcare delivery. This review highlights how AI-driven technologies, including machine learning, deep learning, natural language processing, and predictive analytics, are being successfully applied across the entire drug life cycle to enhance efficiency, reduce costs, and improve decision-making.AI has demonstrated significant impact in early-stage drug discovery through rapid target identification, virtual screening, and lead optimization, while in preclinical and clinical phases it supports safety prediction, patient recruitment, and trial optimization. Furthermore, AI-enabled pharmaceutical manufacturing and pharmacovigilance systems improve product quality, regulatory compliance, and post-marketing drug safety. The growing role of AI in pharmacy practice and healthcare delivery also emphasizes its contribution to personalized medicine and patient-centered care. Despite these advancements, challenges related to data quality, model transparency, ethical concerns, and regulatory acceptance remain critical barriers to widespread adoption. Addressing these limitations through standardized validation frameworks, explainable AI models, robust data governance, and interdisciplinary collaboration will be essential for sustainable implementation. In conclusion, AI should be regarded as a powerful decision-support tool that complements human expertise rather than replacing it. With continued technological progress, regulatory evolution, and collaborative efforts among academia, industry, and regulatory authorities, AI is poised to play a central role in shaping the future of pharmaceutical sciences and improving global healthcare outcomes.

IX. ACKNOWLEDGMENT

The authors would like to express their sincere gratitude to the faculty and management of Raosaheb Patil Danve College of Pharmacy, Badnapur, for providing the necessary academic support and facilities to carry out this review work.

REFERENCES

[1]. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. *J Health Econ*. 2016;47:20–33.

[2]. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market. *JAMA*. 2020;323(9):844–853.

[3]. Russell S, Norvig P. *Artificial Intelligence: A Modern Approach*. 4th ed. Pearson; 2021.

[4]. Vamathevan J, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov*. 2019;18:463–477.

[5]. Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;26(1):80–93.

[6]. Chen H, Engkvist O, Wang Y, et al. The rise of deep learning in drug discovery. *Drug Discov Today*. 2018;23(6):1241–1250.

[7]. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. *Trends Pharmacol Sci*. 2019;40(8):577–591.

[8]. Lee SL, O'Connor TF, Yang X, et al. Modernizing pharmaceutical manufacturing. *Clin Pharmacol Ther*. 2015;97(1):6–9.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

[9]. Sarker A, Ginn R, Nikfarjam A, et al. Utilizing social media data for pharmacovigilance. *J Biomed Inform*. 2015; 54:202–212.
[10]. Mak KK, Pichika MR. Artificial intelligence in drug development. *Drug Discov Today*. 2019;24(3):773–780.
[11]. Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017;69:S36–S40.
[12]. Bishop CM. Pattern Recognition and Machine Learning. Springer; 2006.
[13]. Nadkarni PM, Ohno-Machado L, Chapman WW. Natural language processing: an introduction. J Am Med Inform Assoc. 2011;18(5):544–551.
[14]. Litjens G, et al. A survey on deep learning in medical image analysis. *Med Image Anal*. 2017;42:60–88.
[15]. Nadkarni PM, Ohno-Machado L, Chapman WW. Natural language processing: an introduction. J Am Med Inform Assoc. 2011;18(5):544–551
[16]. Vamathevan J, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov*. 2019;18:463–477.
[17]. Zhavoronkov A, et al. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. *Mol Pharm*. 2019;16(1):31–39.
[18]. Lavecchia A. Machine-learning approaches in drug discovery. *Drug Discov Today*. 2015;20(3):318–331.
[19]. Elton DC, Boukouvalas Z, Fuge MD, Chung PW. Deep learning for molecular design. *Mol Syst Des Eng*. 2019;4:828–849.
[20]. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic properties. *J Med Chem*. 2015;58(9):4066–4072.
[21]. Walters WP, Murcko MA. Assessing the impact of generative AI on medicinal chemistry. *Nat Biotechnol*. 2020;38:143–145.
[22]. Vamathevan J, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov*. 2019;18:463–477.
[23]. Zhavoronkov A, et al. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. *Mol Pharm*. 2019;16(1):31–39.
[24]. Lavecchia A. Machine-learning approaches in drug discovery. *Drug Discov Today*. 2015;20(3):318–331.
[25]. Elton DC, Boukouvalas Z, Fuge MD, Chung PW. Deep learning for molecular design. *Mol Syst Des Eng*. 2019;4:828–849.
[26]. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic properties. *J Med Chem*. 2015;58(9):4066–4072.
[27]. Walters WP, Murcko MA. Assessing the impact of generative AI on medicinal chemistry. *Nat Biotechnol*. 2020;38:143–145.
[28]. U.S. Food and Drug Administration. *Artificial Intelligence and Machine Learning in Software as a Medical Device*. FDA; 2021.
[29]. Holzinger A, et al. What do we need to build explainable AI systems for the medical domain? *ACM Interact Intell Syst*. 2019;9(2):1–28.
[30]. Price WN, Cohen IG. Privacy in the age of medical big data. *Nat Med*. 2019;25:37–43.
[31]. Char DS, Shah NH, Magnus D. Implementing machine learning in health care—addressing ethical challenges. *N Engl J Med*. 2018;378:981–983.
[32]. World Health Organization. *Ethics and governance of artificial intelligence for health*. WHO; 2021.
[33]. Beam AL, Kohane IS. Big data and machine learning in health care. *JAMA*. 2018;319(13):1317–1318.
[34]. Samek W, Wiegand T, Müller KR. Explainable artificial intelligence. *IEEE Signal Process Mag*. 2017;34(4):54–62.
[35]. Obermeyer Z, et al. Dissecting racial bias in an algorithm used to manage the health of populations. *Science*. 2019;366(6464):447–453.
[36]. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. *Nat Med*. 2019;25:30–36.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, December 2025
Impact Factor: 7.67

[37]. Price WN, Gerke S, Cohen IG. Potential liability for physicians using artificial intelligence. *JAMA*. 2019;322(18):1765–1766.

[38]. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. *Drug Discov Today*. 2019;24(3):773–780.

[39]. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med*. 2015;372:793–795.

[40]. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. *Annu Rev Med*. 2008;59:1–12.

[41]. Bate A, et al. Artificial intelligence in pharmacovigilance: Practical considerations. *Drug Saf*. 2022;45:563–574.

[42]. Topol EJ. Preparing the healthcare workforce to deliver the digital future. *Lancet*. 2019;394:254–262